Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study

BACKGROUND: Generic formulations of imatinib mesylate have been introduced in Western Europe since 2017 to treat patients with chronic myeloid leukemia (CML). However, results on the safety and efficacy of generic formulations are contrasting. The aim of this study was to investigate the safety and...

Descripción completa

Detalles Bibliográficos
Autores principales: Gemelli, Maria, Elli, Elena Maria, Elena, Chiara, Iurlo, Alessandra, Intermesoli, Tamara, Maffioli, Margherita, Pungolino, Ester, Carraro, Maria Cristina, D’Adda, Mariella, Lunghi, Francesca, Anghileri, Michela, Polverelli, Nicola, Rossi, Marianna, Bacciocchi, Mattia, Bono, Elisa, Bucelli, Cristina, Passamonti, Francesco, Antolini, Laura, Gambacorti-Passerini, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536566/
https://www.ncbi.nlm.nih.gov/pubmed/32792470
http://dx.doi.org/10.5045/br.2020.2020130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536566/
https://www.ncbi.nlm.nih.gov/pubmed/32792470
http://dx.doi.org/10.5045/br.2020.2020130

Ejemplares similares